FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2026544265> ?p ?o ?g. }

• W2026544265 endingPage "1412" @default.
• W2026544265 startingPage "1403" @default.
• W2026544265 abstract "This double-blind, 1-year extension study investigated the longterm efficacy and safety of milnacipran 100, 150, and 200 mg/day in the treatment of fibromyalgia (FM) in completers of a 3-month European double-blind lead-in study of milnacipran 200 mg/day versus placebo.A total of 468 patients with FM successfully completing the lead-in study were either blindly maintained on milnacipran 200 mg/day (MLN200:MLN200, n = 198) or (if previously receiving placebo) rerandomized to milnacipran 100 mg/day (PBO:MLN100, n = 91), 150 mg/day (PBO:MLN150, n = 92), or 200 mg/day (PBO:MLN200, n = 87) for an additional 12 months (including a 4-week dose escalation). The main efficacy endpoint was a 2-measure composite responder rate (relative to lead-in study baseline) incorporating the weekly-recall pain score recorded on a visual analog scale and the Patient Global Impression of Change score. A panel of other assessments including the Fibromyalgia Impact Questionnaire explored the multidimensional aspects of FM. Descriptive analyses using the last observation carried forward approach were performed.At the 1-year endpoint, the proportion of composite responders (relative to the lead-in study baseline) ranged from 27.5% (PBO:MLN100) to 35.9% (MLN200:MLN200), and had increased from the extension study baseline by 15.2% (PBO:MLN150) to 20.7% (PBO:MLN200 and MLN200:MLN200). At endpoint, an improvement from both baselines was shown in all groups on pain, fatigue, sleep, and quality of life measures. Up to 1 year, all doses of milnacipran were safe and well tolerated. The most common drug-related adverse events were hyperhidrosis and nausea.Over 1 year, milnacipran 100, 150, and 200 mg/day exhibited sustained and safe therapeutic effects on predominant symptoms of FM. Registered as trial no. NCT00757731." @default.
• W2026544265 created "2016-06-24" @default.
• W2026544265 creator A5033097067 @default.
• W2026544265 creator A5052060110 @default.
• W2026544265 creator A5066076898 @default.
• W2026544265 creator A5087801516 @default.
• W2026544265 date "2011-04-01" @default.
• W2026544265 modified "2023-10-17" @default.
• W2026544265 title "Longterm Therapeutic Response to Milnacipran Treatment for Fibromyalgia. A European 1-Year Extension Study Following a 3-Month Study" @default.
• W2026544265 cites W1583435994 @default.
• W2026544265 cites W1972599056 @default.
• W2026544265 cites W1973637626 @default.
• W2026544265 cites W1988347806 @default.
• W2026544265 cites W1990079987 @default.
• W2026544265 cites W1997284066 @default.
• W2026544265 cites W1998013371 @default.
• W2026544265 cites W2002410186 @default.
• W2026544265 cites W2002718846 @default.
• W2026544265 cites W2003239266 @default.
• W2026544265 cites W2009928888 @default.
• W2026544265 cites W2015678975 @default.
• W2026544265 cites W2020900726 @default.
• W2026544265 cites W2040437210 @default.
• W2026544265 cites W2041481324 @default.
• W2026544265 cites W2049056319 @default.
• W2026544265 cites W2049348898 @default.
• W2026544265 cites W2067495470 @default.
• W2026544265 cites W2071782474 @default.
• W2026544265 cites W2072833030 @default.
• W2026544265 cites W2076962732 @default.
• W2026544265 cites W2078333129 @default.
• W2026544265 cites W2113447800 @default.
• W2026544265 cites W2114732854 @default.
• W2026544265 cites W2123038093 @default.
• W2026544265 cites W2127082049 @default.
• W2026544265 cites W2128447164 @default.
• W2026544265 cites W2132309748 @default.
• W2026544265 cites W2144915944 @default.
• W2026544265 cites W2148029309 @default.
• W2026544265 cites W2153669860 @default.
• W2026544265 cites W2161344815 @default.
• W2026544265 cites W2253364553 @default.
• W2026544265 cites W2313825065 @default.
• W2026544265 cites W279897541 @default.
• W2026544265 cites W3194956376 @default.
• W2026544265 doi "https://doi.org/10.3899/jrheum.101025" @default.
• W2026544265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21459941" @default.
• W2026544265 hasPublicationYear "2011" @default.
• W2026544265 type Work @default.
• W2026544265 sameAs 2026544265 @default.
• W2026544265 citedByCount "26" @default.
• W2026544265 countsByYear W20265442652012 @default.
• W2026544265 countsByYear W20265442652013 @default.
• W2026544265 countsByYear W20265442652014 @default.
• W2026544265 countsByYear W20265442652015 @default.
• W2026544265 countsByYear W20265442652016 @default.
• W2026544265 countsByYear W20265442652017 @default.
• W2026544265 countsByYear W20265442652018 @default.
• W2026544265 countsByYear W20265442652022 @default.
• W2026544265 crossrefType "journal-article" @default.
• W2026544265 hasAuthorship W2026544265A5033097067 @default.
• W2026544265 hasAuthorship W2026544265A5052060110 @default.
• W2026544265 hasAuthorship W2026544265A5066076898 @default.
• W2026544265 hasAuthorship W2026544265A5087801516 @default.
• W2026544265 hasBestOaLocation W20265442651 @default.
• W2026544265 hasConcept C126322002 @default.
• W2026544265 hasConcept C14184104 @default.
• W2026544265 hasConcept C142724271 @default.
• W2026544265 hasConcept C168563851 @default.
• W2026544265 hasConcept C170493617 @default.
• W2026544265 hasConcept C1862650 @default.
• W2026544265 hasConcept C203092338 @default.
• W2026544265 hasConcept C204787440 @default.
• W2026544265 hasConcept C27081682 @default.
• W2026544265 hasConcept C2775864247 @default.
• W2026544265 hasConcept C2777831278 @default.
• W2026544265 hasConcept C2780199185 @default.
• W2026544265 hasConcept C42219234 @default.
• W2026544265 hasConcept C71924100 @default.
• W2026544265 hasConceptScore W2026544265C126322002 @default.
• W2026544265 hasConceptScore W2026544265C14184104 @default.
• W2026544265 hasConceptScore W2026544265C142724271 @default.
• W2026544265 hasConceptScore W2026544265C168563851 @default.
• W2026544265 hasConceptScore W2026544265C170493617 @default.
• W2026544265 hasConceptScore W2026544265C1862650 @default.
• W2026544265 hasConceptScore W2026544265C203092338 @default.
• W2026544265 hasConceptScore W2026544265C204787440 @default.
• W2026544265 hasConceptScore W2026544265C27081682 @default.
• W2026544265 hasConceptScore W2026544265C2775864247 @default.
• W2026544265 hasConceptScore W2026544265C2777831278 @default.
• W2026544265 hasConceptScore W2026544265C2780199185 @default.
• W2026544265 hasConceptScore W2026544265C42219234 @default.
• W2026544265 hasConceptScore W2026544265C71924100 @default.
• W2026544265 hasIssue "7" @default.
• W2026544265 hasLocation W20265442651 @default.
• W2026544265 hasLocation W20265442652 @default.
• W2026544265 hasOpenAccess W2026544265 @default.
• W2026544265 hasPrimaryLocation W20265442651 @default.

• next